Addex Therapeutics spin-out company, Neurosterix completes phase 1 clinical studies of NTX-253 for schizophrenia: Geneva, Switzerland Friday, October 9, 2026, 17:00 Hrs [IST] Adde ...

Addex Therapeutics ( ADXN) announced that its spin-out company Neurosterix has completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator (PAM) of the muscarinic ...

Welcome to the Addex Therapeutics Report 2026 Half-Year Financial Results and Provides Corporate Update Webcast and ...

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 28, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...

Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their ...

Addex Therapeutics reported its first-half 2026 results while outlining progress across its neurological drug portfolio, ...

Addex Therapeutics appoints Jean-Philippe Rocher as head of pharmaceutical development: Geneva, Switzerland Monday, October 5 ...

Addex Therapeutics ( ) has provided an update. Addex Therapeutics reported its 2026 half-year results, highlighting a tighter financial position alongside strategic progress in it ...

Swiss clinical stage pharma company Addex Therapeutics' shares gained more than 13% to 0.028 francs today, after it announced ...

(ADXN), a clinical-stage biopharmaceutical company, on Friday announced the appointment of Jean-Phillippe Rocher as the Head of Pharmaceutical Development, and a member of the Executive Management.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...